Login / Signup

Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model.

Ágnes BenedictGábor SzabóKinga MarczellBridget DohertySilas Martin
Published in: Journal of the National Comprehensive Cancer Network : JNCCN (2024)
Policy discussions about the evaluation of AAP cannot be complete without assessing its impact on its most important target outcome: patient survival. To date, there has been no estimation of the life year gain delivered by the AAP. Our research shows that substantial number of life years were gained for patients with high unmet need by the cancer therapies approved through the program.
Keyphrases
  • quality improvement
  • healthcare
  • public health
  • palliative care
  • mental health
  • case report
  • papillary thyroid
  • drug administration
  • squamous cell carcinoma
  • advance care planning